Popular on Amzeal
- Aquia Inc. Selected to Support the U.S. Air Force and DoD's Platform One CNAP Team on its Mission to Modernize Federal Government's Cybersecurity - 149
- Aquia Inc. Announces Support of Platform One's Iron Bank in an Effort to Centralize and Standardize Application Hardening Throughout the DoD - 129
- San Diego Patch Company sets up www.MauiStrong.help site to help raise money for the residents of Maui - 110
- Fake Tech Job Claims, Do Not Always Mean Fake Technology! Say Developers At Uafab Technologies
- UVify at the 2023 Commercial UAV Expo: Leading the Way with World-Dominating Swarm Light Show Technologies and Advanced Autonomous Drone Platforms
- Entrinsik's User Conference, Entrinsicon 2023, Returns to Raleigh!
- Prince Oakleyski Eurasia will release a film for God's sake. The movie title is "Monotheism and Devils", directed by Prince Oak Oakleyski
- Moolwan releases 10 new Home Decor Items to help customers decorate their homes into opulent masterpieces
- Former DEI Officer Poised to Resume Work in Civil Rights Space After Addressing False Allegations
- Trendsetting@Work Launches M-PACT™ Investment Round; CEO Challenges Norms
Similar on Amzeal
- Higi Selects ThoroughCare to Assist in Managing Chronically Ill Patients
- New Study Finds Wide Disparities in Bicycle Safety Across U.S. Cities
- RelyMD Bolsters its Telehealth Platform with Mental Health Services via CuraLinc Partnership
- Live Good Inc. Celebrates Diversity and Unity: A Beacon of Progress in the Spirit of Crissy Field, Angel Island and the Buffalo Soldiers
- Maryland Sedation Dentistry and Surgical Center Opens in Frederick Maryland
- The 2023 CGI Integrated Care Conference Explores Opportunities in Healthcare Improvement Discovered as a Result of the COVID-19 Pandemic
- Instant Gourmet Coffee With The Authentic Taste & Refreshing Smell Of Cafe De Olla, Infused With The Wonderful Health Benefits Of Superfoods
- Sparkling Logic Launching Generative AI-Powered Tool for Decision Management
- Mountain Fresh Water Systems Announces 5% End-of-Summer Discount on All Services
- Tony Schulte Joins IntellaTriage as New Chief Operating Officer
German skin cancer patients join the EPIC-Skin study
Amzeal News/10487049
ROSTOCK, Germany - Amzeal -- OncoBeta® GmbH has announced University Clinic of Rostock (is particpating in the global phase IV EPIC-Skin Study (Efficacy of Personalised Irradiation with Rhenium-SCT – for the treatment of non-melanoma skin cancer [NMSC]) treating its first patients with Rhenium-SCT® as part of the international study.
The first German patients were treated on 21st July, and are now part of 210 adults participating in the international study that will follow their progress over the next 24 months. The EPIC-Skin study is being conducted through study centres located in Australia, Austria, United Kingdom and Germany.
Rhenium-SCT® has been used in Rostock and in other parts of Germany as an NMSC treatment for some time. In addition to this EPIC-Skin Study, The University Clinic of Rostock has also been involved in a local clinical study using Rhenium-SCT, with results due to be presented later this year.
Treating physician in the EPIC-Skin study - University Clinic of Rostock, Dr. Martin Heuschkel (Nuclear Medicine) said, "Rhenium-SCT® is viewed as a favourable treatment due to its ability to be applied directly to an affected area, without harming or scarring surrounding tissue. This study presents the unqiue opportunity to further evaluate this new non-invasive epidermal radioisotope therapy and its long-term efficacy in improving patient outcomes."
There are more than 7.7 million cases of NMSC each year, and incidence rates are increasing globally1,2 with Germany currently ranked 8th in the world3. Standard treatments for NMSCs are surgery-based approaches, which may have a risk of scarring or loss of function. Rhenium-SCT® uses a non-invasive paste containing ß-emitting particles directly to the lesion, which eliminate cancer cells without the need for surgery, in one single session.4-6
Dr Gerhard Dahlhoff, Medical Director at OncoBeta GmbH, says, "The role of the EPIC-Skin Study is not to challenge the existing treatment options but rather to show Rhenium-SCT® is a treatment alternative with which NMSCs can be cured effectively, with a strong focus on patient perspectives."
The EPIC-Skin study will measure Patient Reported Outcomes such as quality of life, treatment comfort and cosmetic outcomes, as well as further evaluating the efficacy of Rhenium-SCT for the treatment of NMSC. To provide a simple and streamlined way to record their experiences, patients in the study will utilise OncoBeta's Clinical Study app.
More on Amzeal News
Shannon D. Brown III, CEO and Managing Director at OncoBeta, says, "OncoBeta's goal is to provide the best innovative solutions for patients suffering from NMSCs. Rostock is the second centre in Europe participating in the EPIC-Skin study provding important multi-centre data that will offer new insights in the treatment of NMSC's and the role of Rhenium-SCT® as a treatment alternative for patients."
Clinicians who are interested in enrolling patients in the study can contact OncoBeta directly at www.oncobeta.com/contact.
About the Rhenium-SCT® (Skin Cancer Therapy)
Non-melanoma skin cancer (NMSC) is the most common form of cancer in humans.2 The most common cause of NMSC is sun exposure, while other predisposing factors include genetic skin conditions and immunosuppressive diseases or treatments.7
The Rhenium-SCT® is a painless*, single session†, non-invasive therapy providing for unparalleled aesthetic results, even in cases otherwise considered difficult to treat.4-6 The Rhenium-SCT utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). The Rhenium-SCT is a precise, personalised therapy that is only applied to the area needed to treat without affecting the healthy tissue. The specially designed device ensures the Rhenium-SCT compound never comes in direct contact with the patient's skin and the application is safe and simple for the applying physician. Most cases of NMSCs (Basal Cell Carcinomas and Squamous Cell Carcinomas) can be treated using the Rhenium-SCT in one single session.†6 Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.6
About OncoBeta®
OncoBeta®, with its headquarters located in Garching near Munich, Germany, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies. Since its foundation, OncoBeta has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting NMSCs. OncoBeta has perfected the customized application and device management system in conformity with all health, safety and environmental protection regulatory standards.
More on Amzeal News
Find out more about the Rhenium-SCT® at www.oncobeta.com
Follow us on social media:
LinkedIn: www.linkedin.com/company/oncobeta-gmbh/
Facebook: www.facebook.com/oncobeta/
Instagram: www.instagram.com/oncobeta_gmbh/
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control, and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
*No reported pain4,5
†Complete tumour regression in 98.5% of lesions treated6
References
The first German patients were treated on 21st July, and are now part of 210 adults participating in the international study that will follow their progress over the next 24 months. The EPIC-Skin study is being conducted through study centres located in Australia, Austria, United Kingdom and Germany.
Rhenium-SCT® has been used in Rostock and in other parts of Germany as an NMSC treatment for some time. In addition to this EPIC-Skin Study, The University Clinic of Rostock has also been involved in a local clinical study using Rhenium-SCT, with results due to be presented later this year.
Treating physician in the EPIC-Skin study - University Clinic of Rostock, Dr. Martin Heuschkel (Nuclear Medicine) said, "Rhenium-SCT® is viewed as a favourable treatment due to its ability to be applied directly to an affected area, without harming or scarring surrounding tissue. This study presents the unqiue opportunity to further evaluate this new non-invasive epidermal radioisotope therapy and its long-term efficacy in improving patient outcomes."
There are more than 7.7 million cases of NMSC each year, and incidence rates are increasing globally1,2 with Germany currently ranked 8th in the world3. Standard treatments for NMSCs are surgery-based approaches, which may have a risk of scarring or loss of function. Rhenium-SCT® uses a non-invasive paste containing ß-emitting particles directly to the lesion, which eliminate cancer cells without the need for surgery, in one single session.4-6
Dr Gerhard Dahlhoff, Medical Director at OncoBeta GmbH, says, "The role of the EPIC-Skin Study is not to challenge the existing treatment options but rather to show Rhenium-SCT® is a treatment alternative with which NMSCs can be cured effectively, with a strong focus on patient perspectives."
The EPIC-Skin study will measure Patient Reported Outcomes such as quality of life, treatment comfort and cosmetic outcomes, as well as further evaluating the efficacy of Rhenium-SCT for the treatment of NMSC. To provide a simple and streamlined way to record their experiences, patients in the study will utilise OncoBeta's Clinical Study app.
More on Amzeal News
- USA Marketing Pros Launches Limited-Time Discount on One-Page Websites
- Chief Gene Saunders Founder of Project Lifesaver International Selected to Appear on Spotlight Television
- The Luxe Team at Dale Sorensen Real Estate Brevard Presents 100 Ocean Condominium in Melbourne, Florida
- mpathic Achieves SOC 2 Type II Certification, Demonstrating Commitment to Data Security & Compliance
- Generative AI To Spur Growth of Quantum Computing
Shannon D. Brown III, CEO and Managing Director at OncoBeta, says, "OncoBeta's goal is to provide the best innovative solutions for patients suffering from NMSCs. Rostock is the second centre in Europe participating in the EPIC-Skin study provding important multi-centre data that will offer new insights in the treatment of NMSC's and the role of Rhenium-SCT® as a treatment alternative for patients."
Clinicians who are interested in enrolling patients in the study can contact OncoBeta directly at www.oncobeta.com/contact.
About the Rhenium-SCT® (Skin Cancer Therapy)
Non-melanoma skin cancer (NMSC) is the most common form of cancer in humans.2 The most common cause of NMSC is sun exposure, while other predisposing factors include genetic skin conditions and immunosuppressive diseases or treatments.7
The Rhenium-SCT® is a painless*, single session†, non-invasive therapy providing for unparalleled aesthetic results, even in cases otherwise considered difficult to treat.4-6 The Rhenium-SCT utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). The Rhenium-SCT is a precise, personalised therapy that is only applied to the area needed to treat without affecting the healthy tissue. The specially designed device ensures the Rhenium-SCT compound never comes in direct contact with the patient's skin and the application is safe and simple for the applying physician. Most cases of NMSCs (Basal Cell Carcinomas and Squamous Cell Carcinomas) can be treated using the Rhenium-SCT in one single session.†6 Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.6
About OncoBeta®
OncoBeta®, with its headquarters located in Garching near Munich, Germany, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies. Since its foundation, OncoBeta has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting NMSCs. OncoBeta has perfected the customized application and device management system in conformity with all health, safety and environmental protection regulatory standards.
More on Amzeal News
- How to Apply Online for a Loan that pays You in 24 hours
- Metro Commercial Miami Team Doubles
- Wave2 Launches New Dynamic Data Integration Features to Elevate Bank and Credit Union Convenience
- Introducing the TCG-4lite: Streamlined Connectivity for Mobile Machines
- Texas Advocacy Project Aids 10k+ Abuse Victims Annually; Offers Subject Matter Experts for Domestic Violence Awareness Month
Find out more about the Rhenium-SCT® at www.oncobeta.com
Follow us on social media:
LinkedIn: www.linkedin.com/company/oncobeta-gmbh/
Facebook: www.facebook.com/oncobeta/
Instagram: www.instagram.com/oncobeta_gmbh/
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control, and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
*No reported pain4,5
†Complete tumour regression in 98.5% of lesions treated6
References
- Global Burden of Disease Cancer Collaboration, et al. JAMA Oncol. 2019;5(12):1749-1768.
- Ciążyńska M, et al. Sci Rep. 2021;11(1):4337.
- https://www.wcrf.org/cancer-trends/skin-cancer-statistics/
- Cipriani C, et al. J Dermatolog Treat. 2020; Jul 22:1-7.
- Sedda AF, et al. Clin Exp Dermatol. 2008;33(6):745-749.
- Cipriani C, Sedda AF. Epidermal Radionuclide Therapy - Dermatological High-Dose-Rate. Brachytherapy for the Treatment of Basal and Squamous Cell Carcinoma. In: Therapeutic Nuclear Medicine, editor Baum RP; New York: Springer, 2014.
- Cancer.net. Skin Cancer (Non-Melanoma): Risk Factors and Prevention. October 2020. https://www.cancer.net/cancer-types/skin-cancer-non-melanoma/risk-factors-and-prevention (accessed November 2021).
Source: OncoBeta GmbH
0 Comments
Latest on Amzeal News
- AMERICAST Provides PreCast Pads to Charge Stations
- Woman-Owned Technology Studio in Austin Celebrates Milestone With Initiative to Empower Girls
- Sheila Stubbs Taylor of Detroit music royalty is "Chasing" on new single
- Sidow Sobrino Announces 12th Album, "Seminal"
- Heartland Soccer Association and VidSport Launch Groundbreaking Live Streaming Service at Garmin Olathe Soccer Complex
- LogicGate Launches Automated Evidence Collection Feature for Risk Cloud Platform
- Krish Radiant Solutions Inc.: Leading the Way in Innovative IT Solutions
- Maryland Sedation Dentistry and Surgical Center Opens in Frederick Maryland
- LokiBots is one of the 35 early-stage Generative AI startups selected for AWS ML Elevate program 2023 cohort
- Mil-Spec Safety & Security Launches New Website
- Trinity Prairie Real Estate Lists Mesmerizing 16.78-Acre Estate in Colleyville, Texas
- Rhody Rug Revolutionizes Online Shopping Experience with the Launch of their New Direct-to-Consumer Website
- Long Island businessman turned recording artist, John Beyer, to release his first love song aptly titled, …"Love You More"
- The 2023 CGI Integrated Care Conference Explores Opportunities in Healthcare Improvement Discovered as a Result of the COVID-19 Pandemic
- Talk to Steve Jobs, Marilyn Monroe, and even Dead Presidents
- Exploring the World of Web3? Lympid Puts Users Front and Center
- Alary Technologies Nominated for Greater Oshawa Chamber of Commerce's 2023 Business Excellence Awards
- "Regenerating Life": documentary film challenges current assumptions about climate change
- Successful Serial Entrepreneur's Event Aims To Educate, Encourage & Elevate Women Podcasters During National Women's Small Business Month
- Flint's Got Talent Returns To Showcase Creativity In Community